Kevin Morgan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6327746/publications.pdf

Version: 2024-02-01

162 papers	22,401 citations	43973 48 h-index	10424 139 g-index
183 all docs	183 docs citations	183 times ranked	23988 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
2	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
3	TREM2 Variants in Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 117-127.	13.9	2,385
4	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
5	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
6	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
8	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
9	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	13.7	425
10	Common polygenic variation enhances risk prediction for Alzheimerâ€™s disease. Brain, 2015, 138, 3673-3684.	3.7	359
11	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	1.1	347
12	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
13	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
14	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
15	Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease. Archives of Neurology, 2010, 67, 961-4.	4.9	188
16	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
17	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
18	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimerâ€™s disease. International Journal of Biochemistry and Cell Biology, 2003, 35, 1505-1535.	1.2	172

#	Article	IF	Citations
19	Serpins: structure, function and molecular evolution. International Journal of Biochemistry and Cell Biology, 2003, 35, 1536-1547.	1.2	171
20	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
21	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
22	Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. American Journal of Psychiatry, 2019, 176, 811-819.	4.0	123
23	SERPINA3 (aka alpha-1-antichymotrypsin). Frontiers in Bioscience - Landmark, 2007, 12, 2821.	3.0	116
24	Alphaâ€1â€Antitrypsin Deficiency. , 2004, , 42-46.		115
25	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	1.5	110
26	Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. European Heart Journal, 2014, 35, 1078-1087.	1.0	107
27	A Polymorphism in the Tumor Necrosis Factor-Î± Gene Promoter Region May Predispose to a Poor Prognosis in COPD. Chest, 2000, 118, 971-975.	0.4	104
28	The three new pathways leading to Alzheimer's disease. Neuropathology and Applied Neurobiology, 2011, 37, 353-357.	1.8	103
29	Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. Brain, 2020, 143, 3763-3775.	3.7	100
30	Gene regulation of the serine proteinase inhibitors Î±1-antitrypsin and Î±1-antichymotrypsin. Biochemical Society Transactions, 2002, 30, 93-98.	1.6	99
31	Prokineticin 1 Signaling and Gene Regulation in Early Human Pregnancy. Endocrinology, 2008, 149, 2877-2887.	1.4	95
32	Cystic Fibrosis, Disease Severity, and a Macrophage Migration Inhibitory Factor Polymorphism. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1412-1415.	2.5	88
33	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
34	A meta-analysis of epigenome-wide association studies in Alzheimerâ€™s disease highlights novel differentially methylated loci across cortex. Nature Communications, 2021, 12, 3517.	5.8	72
35	Association of MMP - 12 polymorphisms with severe and very severe COPD: A case control study of MMPs - 1, 9 and 12in a European population. BMC Medical Genetics, 2010, 11, 7.	2.1	70
36	Alzheimerâ€™s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry, 2019, 9, 154.	2.4	69

#	Article	IF	Citations
37	Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study. Molecular Neurodegeneration, 2011, 6, 54.	4.4	67
38	Genetic variability in response to amyloid beta deposition influences Alzheimerâ€™s disease risk. Brain Communications, 2019, 1, fcz022.	1.5	67
39	A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene. Brain, 2021, 144, 3727-3741.	3.7	65
40	Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone. Biochemical and Biophysical Research Communications, 2003, 310, 594-599.	1.0	63
41	Replication of BIN1 Association with Alzheimer's Disease and Evaluation of Genetic Interactions. Journal of Alzheimer's Disease, 2011, 24, 751-758.	1.2	61
42	Review: The genetics of <scp>A</scp>lzheimer's disease; putting flesh on the bones. Neuropathology and Applied Neurobiology, 2014, 40, 97-105.	1.8	61
43	Cryptic haplotypes ofSERPINA1confer susceptibility to chronic obstructive pulmonary disease. Human Mutation, 2006, 27, 103-109.	1.1	59
44	Investigation of 15 of the top candidate genes for late-onset Alzheimerâ€™s disease. Human Genetics, 2011, 129, 273-282.	1.8	57
45	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 11.	4.4	57
46	Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. European Journal of Human Genetics, 1999, 7, 659-663.	1.4	56
47	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
48	A polymorphism of the alpha1-antitrypsin gene represents a risk factor for liver disease. Hepatology, 2008, 47, 127-132.	3.6	55
49	The Role of Variation at AÎ²PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	1.2	53
50	Investigating the role of rare coding variability in Mendelian dementia genes (APP , PSEN1 , PSEN2 , GRN) Tj ETQq0 0 0 rgBT /Overlock 1	1.5	53
51	Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2007, 16, 2199-2208.	1.4	51
52	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiology of Aging, 2012, 33, 202.e1-202.e13.	1.5	51
53	The dopamine Î²-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Medical Genetics, 2010, 11, 162.	2.1	50
54	Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2012, 28, 625-636.	1.2	50

#	Article	IF	Citations
55	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, AÃŸ, and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	1.1	48
56	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.4	48
57	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. Journal of Neuroinflammation, 2009, 6, 22.	3.1	46
58	Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiology of Aging, 2012, 33, 1849.e5-1849.e18.	1.5	43
59	A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. Molecular Psychiatry, 2020, 25, 629-639.	4.1	42
60	The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Medical Genetics, 2011, 12, 24.	2.1	39
61	An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. European Journal of Human Genetics, 2001, 9, 273-278.	1.4	38
62	Prokineticin 1 modulates IL-8 expression via the calcineurin/NFAT signaling pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1315-1324.	1.9	38
63	Mutation in an Î±1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of cooperativity between transcription factors. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1362, 67-76.	1.8	37
64	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	1.5	37
65	A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimerâ€™s disease. Neurobiology of Aging, 2005, 26, 449-453.	1.5	36
66	The sex-specific associations of the aromatase gene with Alzheimerâ€™s disease and its interaction with IL10 in the Epistasis Project. European Journal of Human Genetics, 2014, 22, 216-220.	1.4	35
67	Wholeâ€exome sequencing of the <scp>BDR</scp> cohort: evidence to support the role of the <scp>PILRA</scp> gene in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2018, 44, 506-521.	1.8	35
68	The SERPINE2 Gene and Chronic Obstructive Pulmonary Disease. American Journal of Human Genetics, 2006, 79, 184-186.	2.6	34
69	Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. European Respiratory Journal, 2008, 32, 931-937.	3.1	34
70	Influence of Coding Variability in APP-AÎ² Metabolism Genes in Sporadic Alzheimerâ€™s Disease. PLoS ONE, 2016, 11, e0150079.	1.1	34
71	A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 587-597.	1.2	33
72	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. Neurobiology of Aging, 2018, 66, 179.e17-179.e29.	1.5	32

#	Article	IF	Citations
73	Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank. Annals of the Rheumatic Diseases, 2021, 80, 1220-1226.	0.5	32
74	Regulation of the serine proteinase inhibitor (SERPIN) gene Î±1-antitrypsin: A paradigm for other SERPINs. International Journal of Biochemistry and Cell Biology, 1997, 29, 1501-1511.	1.2	31
75	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2018, 62, 244.e1-244.e8.	1.5	30
76	Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1309.e1-1309.e7.	1.5	29
77	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
78	HLA class I, II & III genes in confirmed late-onset Alzheimer's disease. Neurobiology of Aging, 2001, 22, 71-77.	1.5	28
79	Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V and p.S230R) in British early-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2422.e13-2422.e16.	1.5	28
80	Na+/H+ exchange is increased in sickle cell anemia and young normal red cells. Journal of Membrane Biology, 1990, 116, 107-115.	1.0	27
81	Health, social functioning, and marital status: Stability and change among elderly recently widowed women. International Journal of Geriatric Psychiatry, 1992, 7, 813-817.	1.3	27
82	Polymorphism in the alpha1-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Human Genetics, 2001, 109, 303-310.	1.8	27
83	Oncostatin M induced Î±1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3â€² enhancer. Biochemical Journal, 2002, 365, 555-560.	1.7	27
84	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
85	Point mutation in a 3â€² flanking sequence of the alpha-1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence. Human Molecular Genetics, 1993, 2, 253-257.	1.4	26
86	Microsatellite polymorphism of the Î± 1 -antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Human Genetics, 1996, 99, 27-31.	1.8	26
87	The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neuroscience Letters, 2007, 416, 66-70.	1.0	26
88	Rationalising the role of Keratin 9 as a biomarker for Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 22962.	1.6	26
89	Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimerâ€™s disease. Human Genetics, 2018, 137, 305-314.	1.8	25
90	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23

#	Article	IF	Citations
91	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	1.1	23
92	Interactions of external and internal H+ and Na+ with Na+/Na+ and Na+/H+ exchange of rabbit red cells: Evidence for a common pathway. Journal of Membrane Biology, 1990, 118, 193-214.	1.0	22
93	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiology of Aging, 2017, 49, 215.e1-215.e8.	1.5	21
94	Psychological stress, cognitive decline and the development of dementia in amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 3618.	1.6	21
95	Interaction of insulin and PPAR-Î± genes in Alzheimerâ€™s disease: the Epistasis Project. Journal of Neural Transmission, 2012, 119, 473-479.	1.4	20
96	Methylation Profiling RIN3 and MEF2C Identifies Epigenetic Marks Associated with Sporadic Early Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2017, 1, 97-108.	1.2	18
97	PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer's disease patients. Neurobiology of Aging, 2009, 30, 1992-1999.	1.5	17
98	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.1	17
99	The characterization of a mutation of the 3â€˜ flanking sequence of the Î±1-antitrypsin gene commonly associated with chronic obstructive airways disease. European Journal of Clinical Investigation, 1992, 22, 134-137.	1.7	14
100	Calcium retention and increased vascular reactivity caused by a hypothalamic sodium transport inhibitor. Clinical Science, 1988, 75, 197-202.	1.8	13
101	A SNP in the ACT gene associated with astrocytosis and rapid cognitive decline in AD. Neurobiology of Aging, 2008, 29, 1167-1176.	1.5	13
102	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
103	Linking Protective GAB2 Variants, Increased Cortical GAB2 Expression and Decreased Alzheimerâ€™s Disease Pathology. PLoS ONE, 2013, 8, e64802.	1.1	13
104	Analysis of Genome-Wide Association Study (GWAS) data looking for replicating signals in Alzheimer's disease (AD). International Journal of Molecular Epidemiology and Genetics, 2010, 1, 53-66.	0.4	13
105	Interactions between PPAR-Î± and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 39-47.	0.4	13
106	Erythrocyte sodium pump activity in human obesity. Clinica Chimica Acta, 1984, 141, 179-187.	0.5	12
107	Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD. European Respiratory Journal, 2007, 30, 810-812.	3.1	12
108	Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 39, 220.e1-220.e7.	1.5	12

#	Article	IF	Citations
109	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
110	Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimerâ€™s disease. BMC Research Notes, 2018, 11, 646.	0.6	12
111	Haplotypes of the alpha-1 antitrypsin gene in healthy controls and Z deficiency patients. Human Mutation, 2004, 24, 535-536.	1.1	11
112	Effects of Alzheimer's peptide and Î±1-antichymotrypsin on astrocyte gene expression. Neurobiology of Aging, 2007, 28, 51-61.	1.5	11
113	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2019, 68, 1535-1547.	1.2	11
114	Association between serum urate, gout and comorbidities: a caseâ€“control study using data from the UK Biobank. Rheumatology, 2021, 60, 3243-3251.	0.9	11
115	Cognitive phenotypes in Alzheimer's disease and genetic variants in ACE and IDE. Neurobiology of Aging, 2012, 33, 1486.e1-1486.e2.	1.5	10
116	Acute and Chronic Performance Evaluation of a Novel Epicardial Pacing Lead Placed by Percutaneous Subxiphoid Approach in a Canine Model. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 659-666.	2.1	10
117	A Fluorescence Resonance Energy Transfer Assay For Monitoring Î±- Synclein Aggregation in a Caenorhabditis Elegans Model For Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2015, 14, 1054-1068.	0.8	10
118	Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid. International Journal of Molecular Epidemiology and Genetics, 2014, 5, 53-70.	0.4	10
119	Genetic risk for Alzheimerâ€™s disease influences neuropathology via multiple biological pathways. Brain Communications, 2020, 2, fcaa167.	1.5	9
120	Prion-like Î±-synuclein pathology in the brain of infants with Krabbe disease. Brain, 2022, 145, 1257-1263.	3.7	9
121	Allele-specific overexpression in astrocytes of an Alzheimer's disease associated alpha-1-antichymotrypsin promoter polymorphism. Molecular Brain Research, 2004, 131, 88-92.	2.5	8
122	Sarcoidosis and MIF gene polymorphism: a case-control study in an Irish population. European Respiratory Journal, 2006, 29, 325-329.	3.1	8
123	Investigating Statistical Epistasis in Complex Disorders. Journal of Alzheimer's Disease, 2011, 25, 635-644.	1.2	8
124	Association of improved pulmonary phenotype in irish cystic fibrosis patients with a 3â€² enhancer polymorphism in alpha-1-antitrypsin. Pediatric Pulmonology, 2006, 41, 584-591.	1.0	7
125	Genetic variants in glutamate-, AÎ²â€“, and tau-related pathways determine polygenic risk for Alzheimer's disease. Neurobiology of Aging, 2021, 101, 299.e13-299.e21.	1.5	7
126	The alpha-1-antitrypsin gene promoter in human A549 lung derived cells, and a novel transcription initiation site. International Journal of Biochemistry and Cell Biology, 2009, 41, 1157-1164.	1.2	6

#	Article	IF	Citations
127	Commentary on Functional analysis of APOE Locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. Journal of Human Genetics, 2012, 57, 3-4.	1.1	6
128	Reverse engineering of Alzheimer's disease based on biomarker pathways analysis. Neurobiology of Aging, 2014, 35, 2029-2038.	1.5	6
129	Genotyping of the Alzheimerâ€™s Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. Journal of Alzheimer's Disease, 2018, 64, 355-362.	1.2	6
130	Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatrica Scandinavica, 1989, 80, 297-298.	2.2	5
131	Transforming growth factor Î²1 regulates angiotensin II type I receptor gene expression in the extravillous trophoblast cell line SGHPL-4. Molecular Human Reproduction, 2005, 11, 847-852.	1.3	5
132	Genome-wide association findings from the brains for dementia research cohort. Neurobiology of Aging, 2021, 107, 159-167.	1.5	5
133	Using Fisher's method with PLINK 'LD clumped' output to compare SNP effects across Genome-wide Association Study (GWAS) datasets. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 30-5.	0.4	4
134	Upregulated expression of FFAR2 and SOC3 genes is associated with gout. Rheumatology, 2023, 62, 977-983.	0.9	4
135	ATP-Binding Cassette, Subfamily A (ABC1), Member 7 (ABCA7). , 2013, , 135-158.		3
136	A reproducible procedure for measuring sodium transport in cultured human fibroblasts from normal and obese donors. Clinica Chimica Acta, 1985, 153, 225-232.	0.5	2
137	Serum stimulation of sodium transport in human fibroblasts containing low and high levels of intracellular sodium. Journal of Membrane Biology, 1986, 92, 163-170.	1.0	2
138	Electoral registration and cognitive impairment among elderly people. International Journal of Geriatric Psychiatry, 1989, 4, 235-237.	1.3	2
139	Multiple Insulin Degrading Enzyme Variants Alter In Vitro Reporter Gene Expression. PLoS ONE, 2011, 6, e21429.	1.1	2
140	Blood type gene locus has no influence on ACE association with Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1767.e1-1767.e2.	1.5	2
141	Membrane-Spanning 4-Domains Subfamily A, MS4A Cluster. , 2013, , 159-179.		2
142	Elastase Inhibitors in the Lung: Expression and Functional Relationships. , 1999, , 69-94.		2
143	Next generation sequencing of CLU, PICALM and CR1: pitfalls and potential solutions. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 262-75.	0.4	2
144	Leukaemic promyelocytes and normal bone marrow cells release a passive sodium transport modifier (inhibitin). Clinical Science, 1985, 68, 365-368.	1.8	1

#	Article	IF	Citations
145	Characterization of Na+ transport in normal human fibroblasts and neoplastic H.Ep.2 cells and the role of inhibitin. Journal of Membrane Biology, 1988, 106, 219-231.	1.0	1
146	The sensitivity of competitive hybridisation for the detection of mutant p53 alleles in a background of wild type. Biochemical Society Transactions, 1995, 23, 129S-129S.	1.6	1
147	Plasmonic-array-based biosensors for the diagnosis of neurodegenerative diseases. , 2011, , .		1
148	Response to: â€˜Correspondence on â€˜Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobankâ€™â€™ by Takei et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220785.	0.5	1
149	Clusterin. , 2013, , 25-51.		1
150	Complement Component (3b/4b) Receptor 1 (CR1). , 2013, , 77-101.		1
151	Using In silico LD clumping and meta-analysis of genome-wide datasets as a complementary tool to investigate and validate new candidate biomarkers in Alzheimer's disease. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 134-44.	0.4	1
152	Transcription termination and DNase I hypersensitive sites in the 3â€² flanking sequence of the alpha-1-antitrypsin gene. Biochemical Society Transactions, 1992, 20, 348S-348S.	1.6	0
153	Simple and efficient cDNA capture utilising a short gene-specific probe attached to magnetic beads. Biochemical Society Transactions, 1994, 22, 453S-453S.	1.6	0
154	P3â€•126: USING RNAâ€SEQ TO IDENTIFY RNA EDITING IN CONTROL AND ALZHEIMER'S DISEASE POSTMORTEM BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P1115.	0.4	0
155	Sialic Acid Binding Immunoglobulin-Like Lectin-3 (CD33). , 2013, , 181-190.		0
156	Erythropoietin-Producing Human Hepatocellular Carcinoma (EphA1). , 2013, , 191-199.		0
157	Bridging Integrator 1 (BIN1). , 2013, , 103-133.		0
158	PICALM. , 2013, , 53-76.		0
159	The Future Role of Biomarkers in Alzheimerâ€™s Disease Diagnostics. , 2013, , 231-248.		0
160	CD2-Associated Protein (CD2AP). , 2013, , 201-208.		0
161	Comment on: Association between serum urate, gout and comorbidities: a caseâ€“control study using data from the UK Biobank: Reply. Rheumatology, 2021, , .	0.9	0
162	Are polymorphisms affecting serum urate, renal urate handling and alcohol intake associated with co-morbidities in gout cases? A caseâ€“control study using data from the UK Biobank. Rheumatology International, 0, , .	1.5	0